BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 21660488)

  • 1. Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.
    Tan Y; Chen Y; You Q; Sun H; Li M
    J Mol Model; 2012 Mar; 18(3):1023-36. PubMed ID: 21660488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain.
    Durdagi S; Duff HJ; Noskov SY
    J Chem Inf Model; 2011 Feb; 51(2):463-74. PubMed ID: 21241063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico prediction of hERG inhibition.
    Jing Y; Easter A; Peters D; Kim N; Enyedy IJ
    Future Med Chem; 2015; 7(5):571-86. PubMed ID: 25921399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A binary QSAR model for classification of hERG potassium channel blockers.
    Thai KM; Ecker GF
    Bioorg Med Chem; 2008 Apr; 16(7):4107-19. PubMed ID: 18243713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining structure- and ligand-based approaches for studies of interactions between different conformations of the hERG K+ channel pore and known ligands.
    Coi A; Bianucci AM
    J Mol Graph Model; 2013 Nov; 46():93-104. PubMed ID: 24185260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
    Ermondi G; Visentin S; Caron G
    Eur J Med Chem; 2009 May; 44(5):1926-32. PubMed ID: 19110341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A composite model for HERG blockade.
    Kramer C; Beck B; Kriegl JM; Clark T
    ChemMedChem; 2008 Feb; 3(2):254-65. PubMed ID: 18061919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers.
    Aronov AM
    J Med Chem; 2006 Nov; 49(23):6917-21. PubMed ID: 17154521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
    Cavalli A; Poluzzi E; De Ponti F; Recanatini M
    J Med Chem; 2002 Aug; 45(18):3844-53. PubMed ID: 12190308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers.
    Thai KM; Ecker GF
    Mol Divers; 2009 Aug; 13(3):321-36. PubMed ID: 19219559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding hERG inhibition with QSAR models based on a one-dimensional molecular representation.
    Diller DJ; Hobbs DW
    J Comput Aided Mol Des; 2007 Jul; 21(7):379-93. PubMed ID: 17549583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive support vector machine binary hERG classification model based on extensive but biased end point hERG data sets.
    Shen MY; Su BH; Esposito EX; Hopfinger AJ; Tseng YJ
    Chem Res Toxicol; 2011 Jun; 24(6):934-49. PubMed ID: 21504223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling.
    Du-Cuny L; Chen L; Zhang S
    J Chem Inf Model; 2011 Nov; 51(11):2948-60. PubMed ID: 21902220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel approach using pharmacophore ensemble/support vector machine (PhE/SVM) for prediction of hERG liability.
    Leong MK
    Chem Res Toxicol; 2007 Feb; 20(2):217-26. PubMed ID: 17261034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of hERG potassium channel affinity by the CODESSA approach.
    Coi A; Massarelli I; Murgia L; Saraceno M; Calderone V; Bianucci AM
    Bioorg Med Chem; 2006 May; 14(9):3153-9. PubMed ID: 16426850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. General Purpose 2D and 3D Similarity Approach to Identify hERG Blockers.
    Schyman P; Liu R; Wallqvist A
    J Chem Inf Model; 2016 Jan; 56(1):213-22. PubMed ID: 26718126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools.
    Moorthy NS; Ramos MJ; Fernandes PA
    J Enzyme Inhib Med Chem; 2014 Jun; 29(3):317-24. PubMed ID: 23560722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine-learning technique, QSAR and molecular dynamics for hERG-drug interactions.
    Das NR; Sharma T; Toropov AA; Toropova AP; Tripathi MK; Achary PGR
    J Biomol Struct Dyn; 2023; 41(23):13766-13791. PubMed ID: 37021352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADMET Evaluation in Drug Discovery. 16. Predicting hERG Blockers by Combining Multiple Pharmacophores and Machine Learning Approaches.
    Wang S; Sun H; Liu H; Li D; Li Y; Hou T
    Mol Pharm; 2016 Aug; 13(8):2855-66. PubMed ID: 27379394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.